EU Provides $113 Million for BioNTech’s COVID-19 Vaccine Program

The EU’s lending arm, the European Investment Bank, is making available up to $113 million in financing for BioNTech’s COVID-19 vaccine program.

The European Investment Bank funding will support global development of BNT162, a messenger RNA-based vaccine, and the scaling up of manufacturing capacity in Europe.

Germany-based BioNTech is developing that vaccine candidate in collaboration with Pfizer.